Molecular design of prostaglandin probes in brain research: High, specific binding to a novel prostacyclin receptor in the central nervous system

Bulletin of the Chemical Society of Japan

Volumn 73, Issue 5, 2000, Pages 1053-1070

  Suzuki, Masaaki ^a   Noyori, Ryoji ^b   Långström, Bengt ^c   Watanabe, Yasuyoshi ^d,e  

^a GIFU UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c UPPSALA UNIVERSITY   (Sweden)

^d OSAKA BIOSCIENCE INSTITUTE   (Japan)

^e OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTACYCLIN; PROSTACYCLIN RECEPTOR;

ARTICLE; BINDING AFFINITY; DRUG INDICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HUMAN TISSUE; NERVE DEGENERATION; NEUROPROTECTION;

EID: 0034075738     PISSN: 00092673     EISSN: None     Source Type: Journal    
DOI: 10.1246/bcsj.73.1053     Document Type: Article

References (110)

1. a) J. R. Vane, Angew. Chem., Int. Ed. Engl., 22, 741 (1983).
2. b) B. Samuelsson, Angew. Chem., Int. Ed. Engl., 22, 805 (1983).
3. c) S. Bergström, Angew. Chem., Int. Ed. Engl., 22, 858 (1983).
4. For recent advance, see: d) "Advances in Prostaglandin, Thromboxane, and Leukotriene Research," Raven Press, New York (1983-1995), Vol. 11-23.
5. e) "Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury 2 (part A and B) and 3," Plenum Press, New York (1997).
6. f) "Prostaglandins, Leukotrienes and Other Eicosanoids," ed by F. Marks and G. Fürstenberger, WILEY-VCH Verlag, New York (1999).
7. a) M. Hirata, Y. Hayashi, F. Ushikubi, Y. Yokota, R. Kageyama, S. Nakanishi, and S. Narumiya, Nature, 349, 617 (1991).
8. b) Review: F. Ushikubi, M. Hirata, and S. Narumiya, J. Lipid Mediat. Cell Signal., 12, 343 (1995).
9. c) R. A. Coleman, W. L. Smith, and S. Narumiya, Pharmacol. Rev., 46, 205 (1994).
10. a) M. Suzuki, M. Mori, T. Niwa, R. Hirata, K. Furuta, T. Ishikawa, and R. Noyori, J. Am. Chem. Soc., 119, 2376 (1997), and references cited therein.
11. b) K. Akimaru, M. Nakanishi, M. Suzuki, K. Furuta, R. Noyori, and T. Ishikawa, "Advances in Experimental Medicine & Biology, 407," "Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury 3," ed by K. V. Honn, L. J. Marnett, S. Nigam, R. L. Jones, and P. Y.-K. Wong, Plenum Press, New York (1997), pp. 387-391.
12. b) K. Akimaru, M. Nakanishi, M. Suzuki, K. Furuta, R. Noyori, and T. Ishikawa, "Advances in Experimental Medicine & Biology, 407," "Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury 3," ed by K. V. Honn, L. J. Marnett, S. Nigam, R. L. Jones, and P. Y.-K. Wong, Plenum Press, New York (1997), pp. 387-391.
13. c) T. Ishikawa, K. Akimaru, M. Nakanishi, K. Tomokiyo, K. Furuta, M. Suzuki, and R. Noyori, Biochem. J., 336, 569 (1998).
14. d) M. Tanikawa, K. Yamada, K. Tominaga, H. Morisaki, Y. Kaneko, K. Ikeda, M. Suzuki, T. Kiho, K. Tomokiyo, K. Furuta, R. Noyori, and M. Nakanishi, J. Biol. Chem., 273, 18522 (1998).
15. See also: e) M. G. Santoro and S. M. Roberts, Drug News Perspect, 12(7), 395 (1999).
16. T. Ohta, Y. Azuma, H. Kanatani, M. Kiyoki, and Y. Koshihara, J. Pharmacol. Exp. Ther., 275, 450 (1995).
17. a) B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, Cell, 83, 803 (1995).
18. b) S. A. Kliewer, J. M. Lenhard, T. M. Willson, I. Patel, D. C. Morris, and J. M. Lehmann, Cell, 83, 813 (1995).
19. S. Takahashi, N. Odani, K. Tomokiyo, K. Furuta, M. Suzuki, A. Ichikawa, and M. Negishi, Biochem. J., 335, 35 (1998).
20. T. Satoh, K. Furuta, M. Suzuki, and Y. Watanabe, Biochem. Biophys. Res. Commun., 258, 50 (1999).
21. a) K. Akimaru, M. T. Kuo, K. Furuta, M. Suzuki, R. Noyori, and T. Ishikawa, Cytotechnology, 19, 221 (1996).
22. b) K. Furuta, K. Tomokiyo, M. T. Kuo, T. Ishikawa, and M. Suzuki, Tetrahedron, 55, 7529 (1999).
23. c) K. Furuta, T. Hosoya, K. Tomokiyo, S. Okuda, A. Kuniyasu, H. Nakayama, T. Ishikawa, and M. Suzuki, Bioorg. Med. Chem. Lett., 9, 2661 (1999).
24. a) G. Hertting and A. Seregi, Ann. N. Y. Acad. Sci., 559, 84 (1989).
25. b) H. Wise, Prog. Drug Res., 49, 123 (1997), and references cited therein.
26. c) K. R. Bley, J. C. Hunter, R. M. Eglen, and J. A. M. Smith, Trends Pharmacol. Sci., 19, 141 (1998).
27. R. Ueno, K. Honda, S. Inoue, and O. Hayaishi, Proc. Natl. Acad. Sci. U.S.A., 1983, 1735.
28. O. Hayaishi, Adv. Prostaglandin Thromboxane Leukot. Res., 12, 333 (1983).
29. a) S. Sato, H. Matsumura, and O. Hayaishi, Eur. J. Pharmacol., 351, 155 (1998).
30. b) Review: Y. Urade and O. Hayaishi, Biochim. Biophys. Acta, 1436, 606 (1999).
31. a) K. Matsumura, C. Cao, Yu. Watanabe, and Y. Watanabe, Prog. Brain Res., 115, 275 (1998).
32. b) C. Cao, K. Matsumura, M. Ozaki, and Y. Watanabe, J. Neurosci., 19, 716 (1999).
33. Y. Sugimoto, T. Namba, R. Shigemoto, M. Negishi, A. Ichikawa, and S. Narumiya, Am. J. Physiol., 266, F823 (1994).
34. S. Moncada, R. Gryglewsky, S. Bunting, and J. R. Vane, Nature, 263, 663 (1976).
35. a) Y. Chiang, A. J. Kresge, and M. J. Cho, J. Chem. Soc., Chem. Commun., 1979, 129.
36. b) Y. Chiang, M. J. Cho, B. A. Euser, and A. J. Kresge, J. Am. Chem. Soc., 108, 4192 (1986).
37. c) K. V. Honn, B. Cicone, and A. Skoff, Science, 212, 1270 (1981).
38. d) S. Moncada, Br. J. Pharmacol., 76, 3 (1982).
39. a) M. Suzuki, H. Koyano, R. Noyori, H. Hashimoto, M. Negishi, A. Ichikawa, and S. Ito, Tetrahedron, 48, 2635 (1992), and references cited therein.
40. b) S. Ito, H. Hashimoto, M. Negishi, M. Suzuki, H. Koyano, R. Noyori, and A. Ichikawa, J. Biol. Chem., 267, 20326 (1992).
41. c) R. Noyori and M. Suzuki, Science, 259, 44 (1993).
42. a) M. Shibasaki, Y. Torisawa, and S. Ikegami, Tetrahedron Lett., 24, 3493 (1983).
43. b) Y. Mizushima, R. Igarashi, K. Hoshi, A. K. Sim, M. E. Cleland, H. Hayashi, and J. Goto, Prostaglandins, 33, 161 (1987).
44. a) W. Skuballa and H. Vorbrüggen, Angew. Chem., Int. Ed. Engl., 20, 1046 (1981).
45. b) W. Skuballa and H. Vorbr̈ggen, Adv. Prostaglandin Thromboxane Leukot. Res., 11, 299 (1983).
46. a) T. Namba, H. Oida, Y. Sugimoto, A. Kakizuka, M. Negishi, A. Ichikawa, and S. Narumiya, J. Biol. Chem., 269, 9986 (1994).
47. b) M. Katsuyama, Y. Sugimoto, T. Namba, A. Irie, M. Negishi, S. Narumiya, and A. Ichikawa, FEBS Lett., 344, 74 (1994).
48. c) O. Nakagawa, I. Tanaka, T. Usui, M. Harada, Y. Sasaki, H. Itoh, T. Yoshimasa, T. Namba, S. Narumiya, and K. Nakao, Circulation, 90, 1643 (1994).
49. d) Y. Sasaki, T. Usui, I. Tanaka, O. Nakagawa, T. Sando, T. Takahashi, T. Namba, S. Narumiya, and K. Nakao, Biochim. Biophys. Acta, 1224, 601 (1994).
50. e) Y. Boie, T. H. Rushmore, A. Darmon-Goodwin, R. Grygorczyk, D. M. Slipetz, K. M. Metters, and M. Abramovitz, J. Biol. Chem., 269, 12173 (1994).
51. a) G. Hertting and A. Seregi, in "Arachidonic Acid Metabolism in the Nervous System," ed by A. I. Barkai and N. G. Bazan, New York Academy of Science, New York (1989), pp. 84-99.
52. b) R. P. White, Ann. N. Y. Acad. Sci., 559, 131 (1989).
53. c) K. U. Malik and E. Sehic, Ann. N. Y. Acad. Sci., 640, 222 (1990).
54. d) R. Gonzales, C. D. Sherbourne, M. E. Goldyne, and J. D. Levine, J. Neurochem., 57, 1145 (1991).
55. e) P. C. Huttemeier, Y. Kamiyama, M. Su, W. D. Watkins, and H. Benveniste, Prostaglandins, 45, 177 (1993).
56. f) C. W. Leffler and H. Parfenova, Am. J. Physiol, 41, H418 (1997).
57. For the induction of COX-2 gene in the CNS, see: g) M. Kawasaki, Y. Yoshihara, M. Yamaji, and Y. Watanabe, Mol. Brain Res., 19, 39 (1993).
58. h) K. Yamagata, K. I. Andreasson, W. E. Kaufmann, C. A. Barnes, and P. F. Worley, Neuron, 11, 371 (1993).
59. i) C. Cao, K. Matsumura, K. Yamagata, and Y. Watanabe, Brain Res., 697, 187 (1995).
60. a) R. J. Gryglewski, Biochem. Pharmacol., 28, 3161 (1979).
61. b) V. T. Miller, B. M. Coull, F. M. Yatsu, A. B. ShaH, and N. B. Beamer, Neurology, 34, 1431 (1984).
62. K. Matsumura, Yu. Watanabe, H. Onoe, and Y. Watanabe, Neuroscience, 65, 493 (1995).
63. E. S. Akarsu and I. H. Ayhan, Methods Find. Exp. Clin. Pharmacol., 14, 517 (1992).
64. H. Oida, T. Namba, Y. Sugimoto, F. Ushikubi, H. Ohishi, A. Ichikawa, and S. Narumiya, Br. J. Pharmacol., 116, 2828 (1995).
65. a) J. S. Fowler, A. P. Wolf, J. R. Barrio, J. C. Mazziotta, and M. E. Phelps, in "Positron Emission Tomography and Autoradiography," ed by M. E. Phelps, J. C. Mazziotta, and H. R. Scheibert, Raven Press, New York (1986), Chaps. 9-11.
66. b) J. S. Fowler and A. P. Wolf, Acc. Chem. Res., 30, 181 (1997).
67. c) M. B. Brennan, Chem. Eng. News, Feb. 19, 26 (1996).
68. d) B. Långström, T. Kihlberg, M. Bergström, G. Antoni, M. Björkman, B. H. Forngren, T. Forngren, P. Hartvig, K. Markides, U. Yngve, and M. Ögren, Acta Chem. Scand., 53, 651 (1999).
69. The Subfemtomole Biorecognition Project (1993-1997) executed between Japan Science and Technology Cooperation and Uppsala University PET Centre.
70. a) P. Gullberg, Y. Watanabe, H. Svärd, O. Hayaishi, and B. Långström, Int. J. Rad. Appl. Instrum. [A], 38, 647 (1987).
71. b) Y. Watanabe, B. Långström, C.-G. Stålnacke, P. G. Gillberg, P. Gullberg, H. Lundqvist, S.-M. Aquilonius, U. Pontén, G. Sperberg, K. Hamada, Y. Watanabe, N. Yumoto, M. Hatanaka, H. Hayashi, and O. Hayaishi, Adv. Prostaglandin Thromboxane Leukot. Res., 19, 398 (1989).
72. P. W. Collins and S. W. Djuric, Chem. Rev., 93, 1533 (1993).
73. H. Takechi, K. Matsumura, Yu. Watanabe, K. Kato, R. Noyori, M. Suzuki, and Y. Watanabe, J. Biol. Chem., 271, 5901 (1996).
74. S. Sugiura, S. Kurozumi, and S. Ikegami, J. Labelled Compds. Radiopharm., 38, 129 (1996).
75. M. Suzuki, K. Kato, R. Noyori, Yu. Watanabe, H. Takechi, K. Matsumura, B. Långström, and Y. Watanabe, Angew. Chem., Int. Ed. Engl., 35, 334 (1996).
76. W. Skuballa, E. Schillinger, C.-S. Stürzebecher, and H. Vorbrüggen, J. Med. Chem., 29, 313 (1986).
77. M. Tanaka, C. Kojima, M. Muramatsu, and H. Tanabe, Arzneimittel-Forschung/Drug Res., 45(II), 967 (1995).
78. a) M. Suzuki, H. Koyano, and R. Noyori, J. Org. Chem., 52, 5583 (1987).
79. b) M. Suzuki, Y. Morita, H. Koga, and R. Noyori, Tetrahedron, 46, 4809 (1990).
80. c) R. Noyori and M. Suzuki. Chemtracts-Org. Chem., 3, 173 (1990).
81. a) T. Tanaka, K. Bannai, A. Hazato, M. Koga, S. Kurozumi, and Y. Kato, Tetrahedron, 47, 1861 (1991).
82. b) K. Manabe, T. Tanaka, S. Kurozumi, and Y. Kato, J. Labelled Compds. Radiopharm., 29, 1107 (1991).
83. c) H. Hammele and H.-J. Gais, Angew. Chem., Int. Ed. Engl., 28, 349 (1989).
84. Yu. Watanabe, K. Matsumura, H. Takechi, K. Kato, H. Morii, M. Björkman, B. Långström, R. Noyori, M. Suzuki, and Y. Watanabe, J. Neurochem., 72, 2583 (1999).
85. T. Murata, F. Ushikubi, T. Matsuoka, M. Hirata, A. Yamasaki, Y. Sugimoto, A. Ichikawa, Y. Aze, T. Tanaka, N. Yoshida, A. Ueno, S. Ohishi, and S. Narumiya, Nature, 388, 678 (1997).
86. Yu. Watanabe, K. Matsumura, T. Murata, S. Narumiya, M. Suzuki, and Y. Watanabe, in preparation.
87. B. Långström and R. F. Dannals, in "Principles of Nuclear Medicine," 2nd ed, ed by H. N. Wagner, Z. Szabo, and J. W. Buchanan, W. B. Saunders, Philadelphia (1995), Sect. 1, Chap. 11.
88. M. Suzuki, H. Doi, M. Björkman, Y. Andersson, B. Långström, Y. Watanabe, and R. Noyori, Chem. Eur. J., 3, 2039 (1997).
89. a) J. K. Stille, Angew. Chem., Int. Ed. Engl., 25, 508 (1986).
90. b) V. Farina, V. Krishnamurthy, and W. J. Scott, Org. React., 50, 1 (1997).
91. D. K. Morita, J. K. Stille, and J. R. Norton, J. Am. Chem. Soc., 117, 8576 (1995).
92. Y. Andersson, A. Cheng, and B. Långström, Acta Chem. Scand., 49, 683 (1995).
93. C. A. Tolman, Chem. Rev., 77, 313 (1977).
94. M. Björkman, Y. Andersson, H. Doi, K. Kato, M. Suzuki, R. Noyori, Y. Watanabe, and B. Långström, Acta Chem. Scand., 52, 635 (1998).
95. Y. Watanabe, M. Suzuki, M. Björkman, K. Matsumura, Yu. Watanabe, K. Kato, H. Doi, H. Onoe, S. Sihver, Y. Andersson, K. Kobayashi, O. Inoue, A. Hazato, L. Lu, M. Bergström, R. Noyori, and B. Långström. Neuroimage, 5, No.4, A1 (1997).
96. a) B. Långström, G. Antoni, P. Gullberg, C. Haldin, P. Malmborg, K. Någren, A. Rimland, and H. Svärd, J. Nucl. Med., 28, 1037 (1987).
97. b) R. A. Ferrieri and A. P. Wolf, Radiochem. Acta, 34, 69 (1983).
98. Paper for the synthesis of 29 is in preparation.
99. M. Suzuki, K. Kato, Yu. Watanabe, T. Satoh, K. Matsumura, Y. Watanabe, and R. Noyori, Chem. Commun., 1999, 307.
100. a) T. Satoh, Y. Ishikawa, Y. Kataoka, Y. Cui, H. Yanase, K. Kato, Yu. Watanabe, K. Nakadate, K. Matsumura, H. Hatanaka, K. Kataoka, R. Noyori, M. Suzuki, and Y. Watanabe, Eur. J. Neurosci., 11, 31 15 (1999).
101. b) Y. Cui, Y. Kataoka, T. Satoh, A. Yamagata, N. Shirakawa, Yu. Watanabe, M. Suzuki, H. Yanase, K. Kataoka, and Y. Watanabe, Biochem. Biophys. Res. Commun., 265, 301 (1999).
102. Y. Enokido and H. Hatanaka, Neuroscience, 57, 965 (1993).
103. Y. Ishikawa, T. Satoh, Y. Enokido, C. Nishio, T. Ikeuchi, and H. Hatanaka, Brain Res., 824, 71 (1999).
104. a) R. P. Simon, J. H. Swan, T. Griffiths, and B. S. Meldrum, Science, 226, 850 (1984).
105. b) A. Buchan and W. A. Pulsinelli, J. Neurosci., 10, 311 (1990).
106. c) L. Zhang, A. Mitani, H. Yanase, and K. Kataoka, J. Neurosci. Res., 47, 440 (1997).
107. M. Fisher, M.-E. Meadows, T. Do, J. Weise, V. Trubetskoy, M. Charette, and S. P. Finklestein, J. Cereb. Blood Flow Metab., 15, 953 (1995).
108. a) D. K. J. E. Von Lubitz, R. C.-S. Lin, and K. A. Jacobson, Eur. J. Pharmacol., 287, 295 (1995).
109. b) D. K. J. E. Von Lubitz, M. Beenhakker, R. C.-S. Lin, M. F. Carter, I. A. Paul, N. Bischofberger, and K. A. Jacobson, Eur. J. Pharmacol., 302, 43 (1996).
110. Unpublished data.